FMT for Children with Recurrent Clostridium difficile Infection George Hylands Russell, MD, MSc 2014 James W. Freston Conference Chicago, Illinois August.

Slides:



Advertisements
Similar presentations
Influenza A – Whats Hot TARRANT Symposium 2012 Kevin Fonseca Clinical Virologist ProvLab
Advertisements

Inflammatory Bowel Disease: Overview
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Pediatric Recipients ISHLT 2009.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26.
Grundtvig Learning Partnership. Athens Association of Alzheimer's Disease and Related Disorders Athens Association of Alzheimers Disease and Related Disorders.
The Increased Burden of Community-Onset Clostridium difficile Infection Aaron Smith, B.S. 1, Brandon Wuerth, B.S. 1, Forest Arnold, D.O., M.Sc. 1 Department.
State of New Jersey Department of Health and Senior Services Patient Safety Reporting System Module 2 – New Event Entry.
SPRING CREEK ELEMENTARY Title I For additional information contact the school at
Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt.
THE COMMONWEALTH FUND Multinational Comparisons of Health Systems Data, 2013 David Squires The Commonwealth Fund November 2013.
Automated Surveillance for Adverse Drug Events at Duke University Health System Peter M. Kilbridge, M.D. Washington University School of Medicine AHRQ.
Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010
Eileen McHale, BSN, MDPH, HAI Coordinator
VAP: A Preventable Disease
For the Healthcare Provider
National Quality Strategy Overview August National Quality Strategy Introduction The Affordable Care Act (ACA) requires the Secretary of the Department.
Influenza and Shingles Vaccines August 2013
Opportunities for Prevention & Intervention in Child Maltreatment Investigations Involving Infants in Ontario Barbara Fallon, PhD Assistant Professor Jennifer.
FAFSA on the Web Preview Presentation December 2013.
Asthma in Minnesota Slide Set Asthma Program Minnesota Department of Health January 2013.
How Should We Monitor, Prevent, and Treat Osteoporosis in IBD? All of Our IBD Patients are at Risk and Therefore all Should Begin Treatment at Diagnosis.
Michael Docktor, MD Boston Children’s Hospital August 16, 2014
A model of outhospital management of H1N1v influenza epidemic by SOS Doctors in Greece. Spyridon G. Barbas, MD, Theodore Spiropoulos, MD, George Peppas,MD,
 Prevents 14 million cases of disease in the US each year  Objectives reflect a mobile world society  People continue to contract diseases that are.
National Quality Strategy Overview January 2014 Each slide includes notes that you can access by selecting “View” and then “Notes Page” in PowerPoint.
Negative Parenting and Late Adolescents’ Mental Health: The Protective Function of Relationships with Grandparents Kristen E. Rabe, Bethany S. Quinn, &
Relapsing and Severe C. difficile Disease Role of Fecal Microbiota Transfer.
HIV/AIDS and Women: An Overview Global HIV/AIDS and Women: Current Challenges and Opportunities Briefing, Rayburn House Office Building Jen Kates, PhD.
2014 PPRNet Annual Meeting August 23, 2014 Oscar F. Lovelace Jr., MD.
CONVENTIONAL TREATMENT OPTIONS SLIDE RESOURCE SET FDX/13/0068/EUb | August 2013.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
1 Circuit 10 – Central Region CBC Performance and Quality Improvement Meeting Scheduled for Wednesday, August 20 th, 2014 at 10 a.m. Data for Week Ended.
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
Unpaid care activities among the Indigenous population: Analysis of the 2011 Census Mandy Yap and Dr. Nicholas Biddle This work is funded by the Commonwealth.
Children with Special Needs
HIGH VALUE CARE GI CONDITIONS CHRONIC DIARRHEA EDWARD LEVINE MD OSUWMC OCTOBER 11, 2014.
Abstract Results continued Reference 1 McDonald LC, Coignard B, Dubberke E, et al. Recommendations for Surveillance of Clostridium difficile-Associated.
Clostridium Difficile (C.diff): Fast Facts. What is Clostridium difficile (C. diff)? C. diff is a bacteria that lives in the intestinal tract of about.
C. Difficile and Fecal Microbiota Therapy
Ulcerative Colitis.
Management of Clostridium difficile Infections
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
Faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in immunocompromised (IC) pts: Efficacy and safety International, multi-centre,
Outline C. difficile infection Fecal microbiota
What is the Deal About FMT? Herbert L. DuPont, MD Director, Center for Infectious Diseases, University of Texas School of Public Health President, Kelsey.
Effect of prolonging Clostridium difficile (CD) treatment on recurrence rate in patients receiving concomitant systemic antibiotic therapy 5-yr retrospective.
Nilofar Rahman, MD RISK OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION WITH PPI USE.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
GI tract infections in IBD: Detection and treatment of Clostridium difficile, CMV and enteric pathogens: Case studies David G. Binion, MD Bruce E. Sands,
R3 민준기 Pf. 이창균. Introduction 1978 – Clostridium difficile major cause of diarrhea – Pseudomembranous colitis associated with the use of antimicrobial.
© 2013 Pearson Education, Inc. Bell Ringer  What is an endospore, and what special characteristics do endospore forming bacteria have?
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Use of Azithromycin and Death from Cardiovascular Causes Whitney Shirley University of Georgia Pharm.D. Candidate 2014.
Clostridium difficile infection (CDI) in the ICU and Clostridium difficile outcomes in the PROSPECT Main Trial Erick Duan MD FRCPC Presented at the CCCTG.
From: Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile InfectionA Randomized Trial Ann Intern Med.
From: Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile InfectionA Randomized Trial Ann Intern Med.
Antimicrobial Therapy (Vancomycin and/or Metronidazole)
Raseen Tariq, MBBS, Renee M. Weatherly, Patricia P
Oral Vancomycin as a Therapeutic Option for PSC
Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute 
C. difficile Update Kim Vermedal, RN, MSN, CIC APIC January 25, 2019.
R. U. Varier, E. Biltaji, K. J. Smith, M. S. Roberts, M. K. Jensen, J
Risk factors for postoperative infection after lower gastrointestinal surgery in patients with inflammatory bowel disease: Findings from a large epidemiological.
Presentation transcript:

FMT for Children with Recurrent Clostridium difficile Infection George Hylands Russell, MD, MSc 2014 James W. Freston Conference Chicago, Illinois August 17, 2015

I have no financial relationships with any commercial entity to disclose

Plan A special population A quick look at the literature NASPGHAN next steps

How is Pediatric RCDI different? C. diff is constitutive flora until after 6 months of age, 10 % carriage rate at 1 year 10 fold rise in incidence from Refractory C. diff is rare. Recurrence risk is about 22-30% as in adults. Community acquired C. diff is more common than in adults 23-43% lack antimicrobial exposure history Up to 38% of previously healthy children with RCDI have NAP1/B1/027 serotype Benson L, et al. Infect Control Hosp Epidemiol. 2007;28(11):1233–1235. Khanna S BL, et al. Clin Infect Dis. 2013;56(10): Janqi S, et al. JPGN. 2010; 51:2-7.

A special population A vulnerable population Potential life-long ramifications? Long-term safety is a longer term concern Registry and follow up data on outcomes and health status particularly interesting and important

Pediatric index case 24 month old girl with community acquired RCDI (6 recurrences) Nasogastric tube delivery Healthy screened paternal donor Safe and well in 24 hours now with 5 years f/u Russell GH, et al. Pediatrics. 2010; 126: e

16 month old with community acquired RCDI (6 recurrences) that began at 11 mos of age after Azithromycin for bronchitis 1 st pediatric case documented with colonoscopic delivery Testing and delivery by FMT Working Group Guidelines (Baaken J, et al. Clin Gastro Hep. 2011; 9: ) Improvement in 24 hours. Safe and well in F/U Kahn S, et al. AmJGastro. 2012; 107:

Largest pediatric case series Patients who received FMT for RCDI between at MGH for Children 2 nasogastric tube delivery/ 8 by colonoscopic delivery 90% success rate Safe in patients with and without Inflammatory Bowel Disease Russell GH, et al. JPGN. 2014; 58(5):

Counted as a failure Redeveloped CDI after re-admission

Russell GH, et al. JPGN. 2014; 58(5): Admitted for severe acute colitis RCDI vs UC 100% better for 5 days then resumed severe bloody diarrhea Never redeveloped CDI Potential fulminant UC flare secondary to FMT?

Russell GH, et al. JPGN. 2014; 58(5):

Role of colonization and the sensitivity of the PCR test No change in symptoms occurred (even when RCDI was cleared) when RCDI was not clearly causative

Columbia experience – Ahead of Print 6 patients with at least 2 RCDI – 4 of whom had comorbidities: IBD, Hirschsprung disease, G-tube dependence Cure rate of 100% All screened parent donors – all received PEG 17 grams BID x 2 days. All by colonoscopy following general FMT Working Group guidelines (Baaken J, et al. Clin Gastro Hep. 2011; 9: ) Potential adverse effect in patient with IBD (developed appendicitis after FMT) Pierog A, et al. JPGN. 2014; /INF

NASPGHAN has sponsored the FMT Special Interest Group Standardize pediatric FMT protocols – Standardize recipient/donor consents – Standardize minimal donor testing – Educate and communicate with the Pediatric GI community – Liaison with adult groups and other professional organizations